unanswered questions in car-t therapies
Published 3 years ago • 109 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
5:39
naturally selected cd7 car-t therapy without genetic manipulations for t-all/lbl
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
1:38
challenges of car-t therapy in the real-world setting
-
3:15
key updates in car-t therapy from eha 2022
-
1:33
patient selection for car-t in all
-
30:16
how to stay positive during your worst days
-
2:05
the cost-effectiveness of car t-cell therapy
-
21:16
flow cytometry tutorial | flow cytometry data analysis | flow cytometry gating
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy
-
1:49
a novel subcutaneous car-t therapy for the treatment of hematological malignancies
-
2:57
novel targeted therapies for the treatment of bpdcn
-
2:44
novel bcma-targeting therapies to treat tce relapsed/refractory multiple myeloma
-
1:44
the curative potential of car-t therapy in multiple myeloma
-
1:07
optimizing car-t therapy: regulating car t-cells in vivo
-
2:50
immunotherapy highlights at ims 2023: bispecific antibodies, car-t cells & unanswered questions
-
3:03
the impact of salvage and bridging therapy on car t-cell therapy outcomes in b-all: an itt analysis
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
1:59
novel car-t constructs being investigated for the treatment of all
-
1:26
impact of recent bendamustine treatment before apheresis on car-t therapy outcomes in lbcl
-
4:16
the challenges with car t-cell therapy for t-all and the progress made to overcome these challenges
-
4:17
novel car t-cell therapies for hematological malignancies: exploring new targets
-
1:53
car-t therapy in multiple myeloma: research blind spots